Cardiac Surgeons Issue ‘Call to Action’ to Improve CABG Outcomes in Women [1]
This article brings attention to the need for representation of women in cardiovascular research trials, with women typically accounting for only 20 percent of participants. This comes following a Lancet commission aimed at reducing the global burden of cardiovascular disease in women. From this, investigators of the ROMA trial have launched ROMA-Women, given that women only represented 15 percent of their sample. The ROMA-Women trial is a nested design, one not previously seen in cardiovascular trials. This is achieved by leveraging the ROMA infrastructure and looks to be the first cardiac surgery trial dedicated to women.